NeuraSignal

NeuraSignal operates at the intersection of neurovascular medical devices, clinical diagnostics, robotics, and healthcare software. Its core differentiation is the automation of transcranial Doppler examinations: the NG2 Intelligent Ultrasound uses a robotic probe, machine-learning-based temporal-window discovery, vessel locking, signal optimization, emboli detection, and shunt-grade assistance. The company targets a practical constraint in cerebral blood-flow monitoring: the availability of highly specialized vascular ultrasound operators. Its products are designed for novice as well as experienced users and connect examination hardware with cloud-based access through the NovaGuide Platform and NovaGuide View. Regulatory and quality positioning is also material, with FDA clearance, Health Canada clearance, U.S. assembly, and processes aligned with ISO 13485:2016 and MDSAP requirements described in its product materials. The 2026 Royal Columbian Hospital collaboration and completed TBI research suggest that NeuraSignal is pursuing both workflow integration and evidence-led adoption rather than selling hardware alone.

NeuraSignal’s trajectory reflects a rapid transition from formation to product commercialization and clinical expansion. The company was formed in 2023 following the acquisition of certain NovaSignal assets, creating a foundation around robotic transcranial Doppler technology. It introduced an updated NG2 system on Nov 13, 2024, then announced Health Canada clearance on Mar 18, 2025, broadening its regulatory footprint beyond the United States. A Apr 10, 2025 update highlighted real-world publications supporting automated PFO screening, indicating movement from product development toward clinical validation. In 2026, the company expanded practical deployment: its Jul 22, 2026 Royal Columbian Hospital collaboration linked NG2 to a hospital stroke workflow, while the Sep 17, 2026 completion of Department of Defense-funded TBI research extended its clinical-research reach. The product portfolio now includes robotic ultrasound hardware, cloud-based data access, accessories, and service support. However, disclosed funding, revenue, headcount growth, and hiring data are unavailable, limiting assessment of financial scale and operating leverage. Current employee information identifies one featured position, while the broader stated employee band is 11–50.